> For Research Purposes Only. Corticorelin (Acthrel) is an FDA-approved diagnostic agent used under medical supervision for pituitary function testing. The information presented here is intended for scientific and educational contexts only and does not constitute medical advice, treatment recommendations, or encouragement of self-administration.
Introduction: A Diagnostic Peptide at the Center of Stress Biology
Corticorelin ovine triflutate — marketed under the brand name Acthrel — is one of the few synthetic peptide hormones to earn FDA approval specifically as a diagnostic tool rather than a therapeutic agent. Approved in 1996 by Ferring Pharmaceuticals, Acthrel occupies a unique and critical position in endocrinology research: it is the synthetic equivalent of ovine corticotropin-releasing hormone (oCRH), a 41-amino-acid peptide that serves as the primary upstream regulator of the hypothalamic-pituitary-adrenal (HPA) axis.
The HPA axis represents one of the body's most important stress-response systems, governing the neuroendocrine cascade that ultimately determines cortisol output from the adrenal cortex. At its apex sits corticotropin-releasing hormone (CRH, also called corticotropin-releasing factor, or CRF) — secreted from the paraventricular nucleus (PVN) of the hypothalamus in response to stressors, circadian rhythms, and homeostatic perturbations. CRH drives adrenocorticotropic hormone (ACTH) release from anterior pituitary corticotroph cells, and ACTH in turn stimulates adrenocortical cortisol synthesis.
Dysregulation anywhere along this axis underlies a spectrum of clinically important disorders: Cushing syndrome (hypercortisolism), adrenal insufficiency, depression, anxiety disorders, and post-traumatic stress disorder. For researchers studying these conditions, corticorelin provides an indispensable pharmacological tool — a precisely characterized, reproducible CRH agonist that can be administered to probe every node of the HPA axis with high experimental fidelity.
This profile covers corticorelin's molecular biology, receptor pharmacology, pharmacokinetics, validated diagnostic protocols, and its expanding role in preclinical and translational research.
---
Molecular Structure: A 41-Amino-Acid Ovine Sequence
Corticorelin is a 41-amino-acid peptide with the following primary sequence:
Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2 . xCF3COOH
The molecular weight is 4,670.35 Daltons. The peptide is formulated as a trifluoroacetate (TFA) salt — a common counterion approach that improves solubility and lyophilized stability for pharmaceutical-grade peptides.
Ovine vs. Human CRH: Why the Ovine Form Dominates Clinical Research
Both ovine CRH (oCRH) and human CRH (hCRH) are 41-amino-acid peptides that share structural homology, yet they differ at 7 of the 41 amino acid positions. Human CRH shares its sequence with rat CRH — both are identical — while the ovine sequence diverges at several positions, particularly in the N-terminal and mid-chain regions.
This seemingly subtle structural difference has meaningful pharmacodynamic consequences. Studies comparing the two forms directly have found that oCRH produces greater and more sustained ACTH responses than hCRH at equivalent molar doses. The superior potency of oCRH is attributed to:
1. Higher binding affinity at the CRF1 receptor (CRFR1) on anterior pituitary corticotroph cells
2. Slower dissociation kinetics from the receptor, prolonging receptor activation
3. Greater resistance to endogenous CRH-binding protein (CRHBP) sequestration in plasma, which neutralizes a portion of circulating CRH
For clinical diagnostic purposes — where reproducibility and signal-to-noise ratio are paramount — the superior potency of oCRH translates to more robust, easier-to-interpret ACTH and cortisol responses. This is why the FDA-approved corticorelin (Acthrel) is the ovine form, and why corticorelin stimulation tests using oCRH are considered the gold standard in distinguishing Cushing's disease from ectopic ACTH syndrome.
---
Mechanism of Action: CRF1 Receptor Signaling and the POMC Cascade
CRF1 Receptor Binding
Corticorelin exerts its biological effects primarily through the corticotropin-releasing factor receptor type 1 (CRF1R), a class B G protein-coupled receptor (GPCR) expressed at high density on anterior pituitary corticotroph cells, as well as throughout the central nervous system — particularly in the amygdala, prefrontal cortex, hippocampus, cerebellum, and brainstem.
The CRF1 receptor features a large extracellular N-terminal domain that participates in initial peptide recognition (the "two-domain" binding model), followed by transmembrane domain engagement that stabilizes the activated receptor conformation. Corticorelin's 41-amino-acid structure allows it to engage both domains with high affinity — a feature shared by endogenous CRH but particularly optimized in the ovine sequence.
Gs/cAMP/PKA Signaling Cascade
Upon corticorelin binding, CRF1R undergoes conformational activation and couples to Gs proteins, triggering the canonical adenylyl cyclase pathway:
1. Gs activation to stimulation of adenylyl cyclase (AC)
2. Increased intracellular cyclic AMP (cAMP) within corticotroph cells
3. Protein kinase A (PKA) activation — cAMP binds regulatory subunits of PKA, releasing catalytic subunits
4. Phosphorylation of downstream targets — including transcription factors (e.g., CREB) and ion channels
5. Calcium influx — via PKA-mediated L-type calcium channel opening, which potentiates exocytosis
6. ACTH exocytosis — secretory granule fusion with the plasma membrane releases pre-formed ACTH
This cAMP-mediated cascade also activates transcription of the proopiomelanocortin (POMC) gene — the large precursor protein from which ACTH, beta-endorphin, beta-lipotropin (beta-LPH), gamma-lipotropin (gamma-LPH), and melanocyte-stimulating hormones (MSH) are all derived through post-translational processing. Corticorelin administration therefore not only triggers acute ACTH release from stored granules but also upregulates long-term corticotroph biosynthetic capacity.
ACTH and the Adrenocortical Cascade
Released ACTH travels via the systemic circulation to the adrenal cortex, where it binds the melanocortin 2 receptor (MC2R) — a GPCR exclusively expressed in adrenocortical cells. MC2R activation triggers another cAMP/PKA cascade within the adrenal zona fasciculata, stimulating:
- •Cholesterol mobilization and uptake (via StAR protein)
- •Steroidogenic enzyme expression (CYP11A1, CYP11B1, and others)
- •Cortisol biosynthesis and secretion
The HPA axis completes its homeostatic loop through glucocorticoid negative feedback: elevated cortisol suppresses both hypothalamic CRH secretion and pituitary ACTH release via glucocorticoid receptor (GR) activation, limiting further cortisol production under basal conditions.
---
Pharmacokinetics
Corticorelin is administered exclusively by intravenous (IV) bolus injection — oral bioavailability is negligible due to proteolytic degradation in the gastrointestinal tract. IV administration provides immediate 100% bioavailability.
Key pharmacokinetic parameters (from the Acthrel prescribing information):
| Parameter | Value |
|---|---|
| Route of administration | IV bolus (over 30 seconds) |
| Onset of ACTH response | ~15 minutes post-injection |
| Peak plasma ACTH | 30-60 minutes |
| Peak cortisol response | 30-60 minutes |
| Half-life (biphasic) | alpha-phase ~6 min; beta-phase ~73 min |
| Plasma protein binding | Partially bound to CRH-binding protein (CRHBP) |
| Elimination | Proteolytic degradation; renal clearance of metabolites |
The biphasic half-life reflects the two-compartment pharmacokinetics typical of peptide hormones: a rapid distribution phase (alpha) as the peptide equilibrates between plasma and extravascular compartments, followed by a slower elimination phase (beta) representing metabolic clearance. The relatively long beta-phase (~73 minutes) is one reason why oCRH produces more sustained ACTH responses than hCRH — consistent with oCRH's greater resistance to CRH-binding protein neutralization.
In diagnostic testing, standard sampling occurs at -15, -1, +15, +30, +45, and +60 minutes relative to injection, capturing both the peak ACTH response (15-30 min) and the subsequent decline.
---
Diagnostic Application: Differentiating Cushing's Disease from Ectopic ACTH Syndrome
The Diagnostic Challenge of ACTH-Dependent Cushing Syndrome
Cushing syndrome — the clinical presentation of chronic glucocorticoid excess — can arise from three distinct sources:
1. Pituitary ACTH-secreting adenoma (Cushing's disease) — the most common form (~70%)
2. Ectopic ACTH secretion from non-pituitary tumors (small cell lung cancer, carcinoid tumors, etc.) — ~15%
3. Adrenal adenoma or carcinoma — ACTH-independent hypercortisolism (~15%)
Once autonomous adrenal hypercortisolism is excluded and ACTH-dependence is confirmed (via plasma ACTH measurement), differentiating pituitary from ectopic ACTH secretion becomes the central diagnostic challenge. This distinction has profound treatment implications — pituitary adenomas are addressed with transsphenoidal surgery, while ectopic tumors require identification and resection of the secreting neoplasm.
The Corticorelin Stimulation Test Protocol
The CRH stimulation test using corticorelin ovine trifluoroacetate is the most reliable noninvasive method for this differentiation (Reimondo et al., Clin Endocrinol (Oxf), 2003, PMID: 12780748).
Standard Protocol:
- •Patient fasts for at least 4 hours prior to the test
- •Intravenous line placed; baseline blood samples collected at -15 and -1 minutes for plasma ACTH and serum cortisol
- •Corticorelin 1 mcg/kg body weight administered as IV bolus over 30 seconds
- •Blood samples collected at +15, +30, +45, and +60 minutes post-injection
- •Plasma ACTH measured by immunoradiometric assay (IRMA) or immunochemiluminometric assay (ICMA); serum cortisol by immunoassay
Interpretation Criteria:
| Response Pattern | Diagnosis |
|---|---|
| ACTH rise >35-50% from baseline | Strongly suggests Cushing's disease (pituitary source) |
| Cortisol rise >20% from baseline | Supports pituitary origin |
| Blunted ACTH/cortisol response | Suggests ectopic ACTH syndrome or primary adrenal disease |
In a landmark multicenter study of 469 patients with ACTH-dependent Cushing syndrome, the CRH stimulation test demonstrated robust diagnostic performance for differentiating Cushing's disease from ectopic ACTH syndrome (PMC9583401). Most patients with Cushing's disease show exaggerated ACTH and cortisol responses, while ectopic ACTH-secreting tumors — which do not express functional CRF1 receptors — fail to respond.
Why Pituitary Adenomas Respond and Ectopic Tumors Do Not
The mechanistic basis for differential CRH responsiveness is the presence or absence of functional CRF1 receptors:
- •Pituitary corticotroph adenomas retain CRF1R expression (often increased) and continue to respond to CRH stimulation, releasing ACTH in a regulated manner
- •Ectopic ACTH-secreting tumors (e.g., bronchial carcinoids, small cell lung cancer) typically lack CRF1R expression and secrete ACTH constitutively, independent of CRH stimulation
This tumor-cell autonomous regulation underlies the differential CRH response pattern — a key principle that makes the corticorelin test diagnostically discriminating.
Inferior Petrosal Sinus Sampling (IPSS) with CRH Stimulation
For cases with discordant or equivocal CRH stimulation test results — or where pituitary MRI is negative or inconclusive — Bilateral Inferior Petrosal Sinus Sampling (BIPSS) provides definitive lateralization and differentiation.
In this invasive procedure, catheters are placed bilaterally in the inferior petrosal sinuses — the venous drainage of the anterior pituitary — as well as a peripheral vein. Simultaneous blood samples are drawn before and after corticorelin administration. A central-to-peripheral ACTH ratio >3 (basal) or >2 (post-CRH) strongly confirms pituitary ACTH secretion. Using this criterion, BIPSS with CRH stimulation achieves sensitivity and specificity exceeding 95% in experienced centers (PMC10197771).
Corticorelin's role in BIPSS is critical — CRH stimulation amplifies the central-to-peripheral ACTH gradient, improving diagnostic resolution for cases where basal sampling alone would be equivocal.
---
CRF Receptors: A Two-Receptor System with Distinct Profiles
CRF1 Receptor (CRFR1)
The CRF1 receptor is the primary mediator of CRH's classical neuroendocrine and behavioral effects. It is highly expressed in:
- •Anterior pituitary (corticotrophs — highest density)
- •Amygdala, hippocampus, cerebral cortex, brainstem
- •Cerebellum (Purkinje cells)
- •Peripheral tissues including the adrenal medulla and gonads
CRF1R is the dominant driver of ACTH release and the principal target of corticorelin's diagnostic and experimental actions. Activation of CRF1R promotes anxiety-like behavior in rodent models (elevated plus maze, social interaction test, fear potentiated startle), and CRF1R knockout mice display reduced anxiety and blunted HPA axis stress responses.
CRF1R antagonists — both peptidic (astressin) and small-molecule (antalarmin, pexacerfont, verucerfont) — are extensively used as tool compounds in preclinical stress and anxiety research, and several have reached clinical trials for major depression, anxiety disorders, and irritable bowel syndrome.
CRF2 Receptor (CRFR2)
The CRF2 receptor exists in three splice variants (CRF2-alpha, CRF2-beta, CRF2-gamma) with distinct expression patterns:
- •CRF2-alpha — predominant CNS form; found in lateral septum, ventromedial hypothalamus, olfactory bulb, dorsal raphe nucleus
- •CRF2-beta — predominant peripheral form; highly expressed in cardiac myocytes, skeletal muscle, gastrointestinal tract, vasculature
- •CRF2-gamma — brain-specific; found in amygdala (humans)
Unlike CRF1R, CRF2R shows preferential binding to urocortins (UCN1, UCN2, UCN3) rather than CRH itself. UCN2 and UCN3 are selective CRF2R agonists, while UCN1 binds both receptor subtypes with roughly equal affinity.
The functional role of CRF2R in HPA axis regulation is complex and context-dependent. CRF2R activation has been proposed to modulate the recovery phase of the stress response — potentially counteracting CRF1R-mediated activation and restoring homeostasis. In cardiovascular research, CRF2-beta activation in cardiac myocytes produces cardioprotective effects, including positive inotropy, vasodilation, and protection against ischemia-reperfusion injury.
Corticorelin itself shows selectivity for CRF1R over CRF2R, making it a valuable tool for isolating CRF1-specific effects in receptor pharmacology experiments.
---
Research Applications: Corticorelin as an Experimental Tool
1. HPA Axis Modulation Studies
Corticorelin is the gold-standard pharmacological tool for activating the HPA axis in a controlled, dose-dependent manner. Because it bypasses the hypothalamus (directly stimulating pituitary corticotrophs), it allows researchers to dissect axis function at specific nodes:
- •Hypothalamic vs. pituitary lesions: Corticorelin normalizes blunted ACTH responses caused by hypothalamic damage while preserving pituitary function — distinguishing hypothalamic from pituitary insufficiency
- •Glucocorticoid feedback dynamics: Pretreatment with dexamethasone before corticorelin injection quantifies the degree of negative glucocorticoid feedback suppression
- •Corticotroph reserve assessment: Measures maximal ACTH secretory capacity of the corticotroph population — critical in post-surgical surveillance after pituitary adenoma resection
2. Anxiety and Stress Biology Models
CRH/corticorelin-based paradigms are foundational tools in preclinical behavioral neuroscience. Intracerebroventricular (ICV) or intranasal CRH administration in rodents reliably induces:
- •Anxiety-like behavior (elevated plus maze, open field test, novelty suppressed feeding)
- •Enhanced fear memory consolidation
- •Potentiated acoustic startle responses
- •Social avoidance and anhedonia
These models are used to evaluate candidate anxiolytics, antidepressants, and CRF1R antagonists. Corticorelin's structural precision — compared to crude CRH extracts — ensures reproducible receptor engagement across laboratories.
3. Corticotroph Biology and POMC Research
Corticotroph cells are electrically excitable secretory cells that display spontaneous action potentials and CRH-induced burst-firing patterns. Corticorelin is used in:
- •Electrophysiology experiments (patch-clamp recordings of corticotroph electrical activity in response to CRH)
- •Real-time ACTH secretion kinetics (microfluidic perifusion systems, live-cell imaging)
- •POMC transcriptional regulation (promoter reporter assays, ChIP experiments for CREB binding)
- •Corticotroph tumor biology (studying pituitary adenoma autonomy, receptor desensitization, feedback resistance)
4. Adrenal Insufficiency Diagnosis
In evaluating secondary adrenal insufficiency (pituitary ACTH deficiency), the corticorelin stimulation test complements the insulin tolerance test (ITT). Whereas the ITT stresses the entire axis through hypoglycemia, the CRH test specifically probes pituitary ACTH secretory reserve. A 2026 prospective study in Frontiers in Endocrinology evaluated serum cortisol cutoff values post-CRH stimulation for diagnosing ACTH deficiency, validating the test's continued clinical and research utility.
5. Neuroinflammation and Brain Edema Research
An investigational application of corticorelin involves brain edema management in glioblastoma patients. Preclinical evidence suggests that CRF receptor activation in central nervous system vasculature may modulate blood-brain barrier permeability. While this application remains experimental, it highlights the peptide's value beyond classical HPA axis investigation.
6. Depression and Psychiatric Research
The HPA axis hyperactivation observed in major depression — elevated CRH, elevated ACTH, hypercortisolism, and impaired negative feedback — makes corticorelin an essential tool for mechanistic research. Dexamethasone-CRH combined tests (the DEX/CRH test) are among the most sensitive biomarker assays for melancholic depression, with hypercortisolism after combined DEX suppression + CRH stimulation distinguishing depressed patients from healthy controls with greater sensitivity than either test alone.
---
Comparison to Human CRH in Research Contexts
| Feature | Corticorelin (Ovine, Acthrel) | Human CRH (hCRH) |
|---|---|---|
| Amino acids | 41 | 41 |
| Sequence identity | Differs at 7 positions from hCRH | Identical to rat CRH |
| CRF1R binding affinity | Higher | Lower |
| Endogenous to humans | No | Yes |
| Plasma binding protein (CRHBP) | Lower susceptibility | Higher susceptibility |
| ACTH response magnitude | Greater and more sustained | Smaller |
| FDA approval | Yes (Acthrel, Ferring) | No (research reagent only) |
| Preferred for clinical tests | Yes | Less common |
For most research applications requiring reliable, potent HPA axis stimulation, corticorelin ovine trifluoroacetate is the preferred choice due to its superior potency and reproducibility.
---
Safety Profile and Adverse Events
Corticorelin is generally well-tolerated at diagnostic doses (1 mcg/kg IV). Adverse effects are typically dose-dependent, transient, and resolve within 5-30 minutes without treatment:
- •Flushing (facial and upper body warmth/redness) — most common; occurs in ~20-60% of subjects; likely mediated by peripheral CRF2R vasodilatory effects
- •Hypotension — mild, transient blood pressure decrease; monitor BP during testing
- •Tachycardia — compensatory response to vasodilation
- •Dyspnea or breathlessness — rare; typically mild
- •Sweating and dizziness — occasionally reported
- •Nausea — infrequent
Higher doses (>3 mcg/kg) produce more pronounced cardiovascular effects. Corticorelin should be used with caution in patients with cardiovascular disease or severe hypertension.
---
Standard Research Concentrations and Formulation
Pharmaceutical formulation (Acthrel):
- •100 mcg lyophilized corticorelin ovine triflutate per vial
- •Excipients: 0.88 mg ascorbic acid, 10 mg lactose, 26 mg cysteine hydrochloride monohydrate
- •Reconstituted in sterile water for injection (2 mL)
- •Storage: 2-8 degrees C, protected from light; reconstituted solution stable up to 8 hours refrigerated
Research reagent concentrations:
- •For in vitro corticotroph stimulation: typically 1-100 nM corticorelin in serum-free media
- •For in vivo rodent IV experiments: 0.3-3 mcg/kg IV bolus (scaling from human diagnostic dose)
- •For ICV administration in rodents: 0.1-1 mcg (in 5-10 microL vehicle) for central behavioral effects
- •For receptor binding assays: competing concentration range 10-12 to 10-6 M for IC50 determination
---
Regulatory Status
Corticorelin ovine triflutate (Acthrel) holds full FDA approval for use as a diagnostic agent for the evaluation of pituitary corticotroph function. It is manufactured by Ferring Pharmaceuticals and was originally approved in 1996 under NDA 020162.
Research-grade corticorelin (both ovine and human forms) is available from multiple suppliers as a CAS-registered synthetic peptide for laboratory use. It is not a controlled substance under DEA scheduling, but commercial distribution for human use outside of the approved FDA-labeled indication is not permitted.
For preclinical laboratory use, corticorelin is purchased as a research reagent and used in accordance with institutional IACUC protocols (animal studies) or IRB-approved human research protocols.
---
Key Scientific References
1. Reimondo G et al. (2003). The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome. Clin Endocrinol (Oxf). PMID: 12780748
2. Niemann LK et al. (1989). The ovine corticotropin-releasing hormone (CRH) stimulation test is superior to the human CRH stimulation test for the diagnosis of Cushing's disease. J Clin Endocrinol Metab. PMID: 2543689
3. Tsigos C and Chrousos GP (2002). Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53(4):865-871. PMID: 12377295
4. Pecori Giraldi F et al. (2022). Biochemical testing to differentiate Cushing's disease from ectopic ACTH syndrome. Pituitary. PMID: 35759056
5. Saugstad JA et al. (2022). Outcome of CRH stimulation test and overnight 8 mg dexamethasone suppression test in 469 patients with ACTH-dependent Cushing's syndrome. PMC9583401
6. Fekete EM and Zorrilla EP (2007). Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28(1):1-27. PMID: 17083971
7. Frontiers in Endocrinology (2026). Defining a serum cortisol cutoff level post-CRH stimulation for diagnosing ACTH deficiency. Front Endocrinol 17. DOI: 10.3389/fendo.2026.1741709
8. Vale W et al. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213(4514):1394-1397. PMID: 6267699
---
Conclusion: Corticorelin as a Research Tool for HPA Axis Science
Corticorelin (Acthrel) occupies an exceptional position among research-grade peptides: it is FDA-approved, precisely characterized, and pharmacologically superior for HPA axis stimulation compared to the endogenous human CRH sequence. Its diagnostic role in Cushing syndrome differentiation is well-established and supported by decades of clinical evidence. Equally important, its use as an experimental tool in stress biology, psychiatric research, corticotroph electrophysiology, and POMC biochemistry continues to generate critical insights into how the HPA axis mediates the human stress response.
For researchers studying neuroendocrinology, anxiety disorders, depression, adrenal insufficiency, or pituitary biology, corticorelin represents one of the most precise pharmacological handles available for controlled HPA axis activation. Its combination of high CRF1 receptor selectivity, defined pharmacokinetics, and FDA-validated diagnostic utility makes it a cornerstone reagent in both clinical and basic science contexts.
---
For research purposes only. This content does not constitute medical advice. Corticorelin (Acthrel) is an FDA-approved diagnostic agent; its use in clinical settings requires physician oversight.